Drug Trial Radar · NCT07816666
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Sep 24, 2026
Primary completion
Sep 29, 2028
Study completion Oct 30, 2031
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT); Ventana Medical Systems, Inc
- First posted
- Sep 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)
Conditions
- Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Platinum-sensitive Relapsed Fallopian Tube Cancer
- Platinum-sensitive Relapsed Primary Peritoneal Cancer
Interventions
Torvutatug samrotecanDrug
FRa targeting antibody drug conjugate Topoisomerase I inhibitor
BevacizumabDrug
Monoclonal antibody inhibitor of Vascular Endothelial Growth Factor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 5 years
Locations
124 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Anchorage, Alaska · Not yet recruiting
Research Site
Miami, Florida · Not yet recruiting
Research Site
Indianapolis, Indiana · Not yet recruiting
Research Site
Shreveport, Louisiana · Not yet recruiting
Research Site
Columbia, Maryland · Not yet recruiting
Research Site
Ann Arbor, Michigan · Not yet recruiting
Research Site
Detroit, Michigan · Not yet recruiting
Research Site
Albany, New York · Not yet recruiting
Research Site
Bay Shore, New York · Withdrawn
Research Site
Buffalo, New York · Not yet recruiting
Research Site
Greenlawn, New York · Withdrawn
Research Site
New Hyde Park, New York · Withdrawn
Research Site
New York, New York · Not yet recruiting
Research Site
New York, New York · Not yet recruiting
Research Site
Rego Park, New York · Withdrawn
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Columbus, Ohio · Withdrawn
Research Site
Mayfield Heights, Ohio · Not yet recruiting
Research Site
Oklahoma City, Oklahoma · Withdrawn
Research Site
Philadelphia, Pennsylvania · Not yet recruiting
Research Site
Willow Grove, Pennsylvania · Not yet recruiting
Research Site
Houston, Texas · Not yet recruiting
Research Site
Salt Lake City, Utah · Not yet recruiting
Research Site
Norfolk, Virginia · Not yet recruiting
Research Site
Morgantown, West Virginia · Not yet recruiting
Research Site
Auchenflower, Australia · Not yet recruiting
Research Site
Blacktown, Australia · Not yet recruiting
Research Site
Clayton, Australia · Not yet recruiting
Research Site
Liverpool, Australia · Not yet recruiting
Research Site
Porto Alegre, Brazil · Not yet recruiting
Research Site
São Caetano do Sul, Brazil · Not yet recruiting
Research Site
São José do Rio Preto, Brazil · Not yet recruiting
Research Site
São José dos Campos, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
Teresina, Brazil · Not yet recruiting
Research Site
Vitória, Brazil · Not yet recruiting
Research Site
Abbotsford British Columbia, British Columbia, Canada · Not yet recruiting
Research Site
Montreal, Quebec, Canada · Not yet recruiting
Research Site
Montreal, Quebec, Canada · Not yet recruiting
Showing 40 of 124 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.